DR REDDYS LABORATORIES supplier risk profile Q1 2026: import footprint, sourcing geography, compliance data.
DR REDDYS LABORATORIES recorded 65 shipments across 8 suppliers in Q1 2026, concentrated in pharmaceutical manufacturing. India accounted for 81.5% of shipment volume, with the vast majority sourced through related entities bearing the DR REDDYS LABORATORIES name. HS Chapter 30 (pharmaceutical products) dominated the import profile, representing 61.5% of all shipments.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
No sanctions watchlist hits were recorded for this importer in Q1 2026. No suppliers registered forced-labor exposure under UFLPA proximity mapping.
8 distinct tier-1 suppliers in Q1 2026
| DR REDDYS LABORATORIES | India | 22 |
| DR REDDY S LABORATORIES | India | 21 |
| DR REDDY S LABORATORIES SEZ F | India | 6 |
| DR REDDY S LABORATORIES SEZ | India | 3 |
| DR REDDYS LABORATORIES SEZ FTO | India | 1 |
Share of Q1 2026 inbound shipments by source country
8 tier-2 + 29 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.